

97 Mount Bethel Road I Warren, NJ 07059 P: 732-595-5414 I F: 732-595-5415 info@claritylabs.com I www.claritylabs.com CLIA # 31D2140149

	••••			V-1 (40 - 1 14 - 14 - 14 - 17 - 14 - 14 - 14 -		
	ACCOUNT INFORMATION			PATIENT INFORMATION		
				Last Name	First Name	
				D.O.B (MM/DD/YY)	Sex	7.5
				Phone (Day)	(Evening)] F
				Insured's Address Apt.		
				City	State Zip	
				,		
	The ordering physician must sign his/her name and indicate constitutes as a certification, that with respect to tests reimburse	d by Medicare, N	Medicaid, or other third party	I voluntarily consent to the collection and testing of my specimen. I certify that the specimen on this form is my own, and that the specimen is fresh and free from adulteration. I certify that the information provided on this form and on the label on the specimen sample is accurate. I authorize Clarity Labs to release the results of this testing		
	payers that the testing is medically necessary and the results wi	I be used in the	e management of the patient.		have read and understood the ABN printed on the backside of th	is form.
	Physician Signature		Date	X Patient Signature	Date	
	THIS SECTION IS TO COMPLETED BY A C	CLINICIAN				
	VALIDATED RISK ASSESSMENT □ LOW □ MODER REASON FOR TEST	ATE □HI	IGH	SPECIMEN INFORMATI	1,000	
	☐ New patient requires COT ☐ Sudder		's medical condition	Date Collected://///	Time: : Collector: d is in range of 32.5-37.7°C (90.5-100°F)	□No
	Patient side effect profile changes Substance Substance Unraliable parient history				0 13 III Turige 01 32.0-37.7 0 (30.0-100 F)	
				ICD 10 CODES	hov	
J	Assess for possible drug-drug interactions The clinician must always document clear medical season and necessity in progress notes.			Please enter diagnosis code(s) in the	3 DOX	
	3 INSURANCE INFORMATION Clien	t Bill 🔲 See	Attached Insurance Forms	,	, , , , , , , , , , , , , , , , , , , ,	
1	Insured's Name (if different from Patient)			RECORD POINT-OF-CA	RE RESULTS & ORDER TESTS	
	B		-	NOTE: If Point-of-Care result is NOT marked, it will default to a Negative (-) result.		
	Primary Insurance Name & Plan / Workers Comp. Carri	er			led by ordering provider: ☐Yes ☐No	BOO 001
	Address (Insurance)			U12 MARIJUANA [THC]	POC POC CONF. POC (RESULT) RESULTS TEST POS (*) NEG (*) POS	POC CONF. S RESULTS TEST NEG (-)
	Policy ID # Group/Plan/E	OUK #		U13 COCAINE [COC]	□ □ □ U10 BENZODIAZEPINE [BZO] □	
۲	□ Cash □ Check Received by:			U23 OPIATES [OPI] U3 AMPHETAMINES [AMP]	U20 METHADONE [MTD] U6 TRICYCLIC ANTIDEPRESSANTS [TCA]	
4	ORDER TESTS	Oral Fluid ((OF)	U3 METHAMPHETAMINE [MET] U26 PHENCYCLIDINE [PCP]	U25 OXYCODONE [OXY]	
	PRESUMPTIVE IMMUNOASSAY TESTING	Oral Fluid ((UF)	U19 ECSTASY [MDMA]	U23 MORPHINE [MOR]	
	UDS OFDS Presumptive immunoassay drug so	eroon only (Hr):	* (OE)**	·		
	UDSC OFDSC Presumptive drug screen and confin	. , , ,	N. (() F ()	FOR LAB USE ONLY	Date://	
	SVT Perform Specimen Validity (Ur) (Cr				,	
	"(AMP, BARB, Banzo, BUP, THC, COC, Ecatosy, ETG, ETCH, GAM, MTD, ECOP, CPL, OXY, PCP, Fant, Spice 1 (JMH-D18), Creatinina, pH, Specific Growing, Oxidoarts) "(AMP, Methamp, Banzo, COC, MTD, BUP, CPL, OXY, PCP, THC)			Received by:	Time: : AM PM	
	CONFIRMATION TESTS BY DRUG CLASS O				s ordered all individual tests present in that drug class wil	I be tested.
	SAMPLE TYPE TEST	TYPE SAI	MPLE TYPE	TEST TYPE	SAMPLE TYPE TEST	TYPE
	Utine(UR) Oral Fluid(OF) U1 ALCOHOL BIOMARKER	1 10000000	JR) Oral Fluid(OF) ILLICITS		Utine(LR) Oral Fluid(0F) OPIOIDS: SYNTHETIC	11- 05
	Et9 (Ethyl Glucuronide),EtS (Ethyl Sulfate) ANTICONVULSANTS	Ur, OF U1	13 OF36 Benzoylecg	onine (Cocaine Metabolite) Ur, OF		Ur, OF
	□ U16 □ OF38 Gabapentin □ U27 □ OF47 Pregabalin	Ur, OF □ U1 Ur, OF □ U1	18 Ketamine ^M	Ur	Acetyl Fentanyl, Alfentani Carfentanil, Remifentanil	Acid Ur
	ANTIDEPRESSANTS U5 SSRI (Serotonergic Class)	Ur U1	19 OF40 MDA (Ecsto		Fentanyl ^M , Sufentanii	Ur, OF
	Citalopram ^M , Duloxetine Fluoxetine ^M , Paroxetine	Ur	B OF31 Methamphe	etamine Ur, OF	EDDP (Methadone Metaboli Methadone	te) Ur, OF Ur, OF
	Sertraline Graze Graze Sertraline Graze Graze	Ur U1	4 CANNABINO	IDS, SYNTHETIC (SPICE) B-22, AB-CHMINACA Ur	U24 OF44 Opiolds and Opiate Analogs Dextromethorphan, Meperidine	
	Amitriptyline, Nortriptyline	Ur, OF	AB-FUBINA	CA, AM2201 4-OH Pentyl Ur	Naloxone, Naltrexone	Ur, OF
	□ U7 NSSRI (Not Otherwise Specified) Bupropion, Venlafaxine ^M	Ur	JWH-018-	Pentanoic acid Ur N-4-OH Pentyl Ur	U28 □ OF48 Propoxyphene ^M U31 □ OF49 Tapentadol ^M	Ur, OF Ur, OF
	Vilazodone □ U8 ANTIPSYCHOTICS	□ U3	JWH-073,		□ U32 □ OF50 Trámadol ^M OPIATE/OPIOIDS	Ur, OF
	Aripiprazole™, Clozapine	Ur	Alpha-PVP,	Butylone (Bath Salt) Ur	□ U23 □ OF43 Opiates	Ur OF
	Haloperidol, Olanzapine ^M Quefiapine ^M , Risperidone ^M	Ur Ur	Mephedrone (tath Salt), MDPV (Bath Salt) Ur (Bath Salt), Methylone (Bath Salt) Ur	Codeine, Dihydrocodeine Hydrocodone ^M ,Hydromorph	one Ur, OF
	U4 ANALGESICS Acetaminophen	Ur U2	ALKALOÍDS	(Bath Salt) Ur	Morphine □ U25 □ OF45 Oxycodone	Ur, OF
	BARBITURATES Butalibital, Phenobarbital	Ur	Lysergic ac	cotine), Mitragynine (Kratom) ^N Ur cid diethylamide (LSD) Ur	Oxycodone ^M , Oxymorphol U29 SEDATIVE HYPNOTICS Tolorion	
	Secobarbital BENZODIAZEPINES Elimitazonam Alexazolami	Ur OF U	Psilocybin	silocybin Metabolite) Ur (Magic Mushroom) Ur	Zaleplon, Zolpidem STIMULANTS	Ur OF
	Flunitrazepam ^M , Alprazolam ^M , Clonazepam ^M Diazepam ^M	Ur, OF U2	Carisoprode	ol, Meprobamate Ur, OF	Amphetamine U3 OF31 Ritalin (Methylphenidate)	Ur, OF Ur
	Oxazepam, Flurazepam™ Lorazepam, Midazolam™	Ur, OF Ur, OF	Cyclobenzo		U21 OTHER U33 Diphenhydramine (Benadryl)	Ur
J	Etizolam, Triazolam™, Temazepam	Ur Ur, OF	™ This test will include paren	nt and/or metabolite of the parent drug.		
(PATIENT PRESCRIBED MEDICATIONS (PIX	ase check all that ap				
	Aprazolam (Xanax) Codelne Gabapentin	 Methamph Methylphe 	enidate 🗌 Oxymorphone	Sativex Zaleplon Secobarbital Zolpidem	Pt Name Date/	/
	Amitriptyline	☐ Midazolan ☐ Morphine ☐ Naloxone	□ PCP	Serraline Zopicione Subovono Othor	Donor Intials Date of Birth/_	/
	Buprenorphine Dextromethorphan Hydromorphone Bupropion Diazepam Imipramine Butabarbital Doxepin Ketamine	☐ Naloxone ☐ Naltrexone ☐ Nordiazep	e Phentermine	Suboxone Other Sufentanii Tapentadoi Other	***PEEL AND PLACE ON SPECIMEN CONTAINER***	
	□ Butalbital □ Duloxetine □ Lorazepam □ Normeperidine □ Pristiq □ Carlsoprodol □ Fentanyl □ Meperidine □ Nortriptyline □ Propoxyphene			☐ Tapentadol ☐ Other ☐ Tramadol ☐ Triazolam	T32100	
	Clasopram Fluoxetine Meprobamate Clonazepam Flunttrazepam Methadone	Olanzapin Oxazepam	e Quetiapine	☐ Venlafaxine ☐ Vilazodone	132100	PEEL
		is not provided	- maporino			

SPECIMEN HANDLING REQUIREMENTS:

Specimen Volume Minimum 30mL - Transported in specimen transport vial (packed in collection cup)

Acceptable Samples - 30mL transported in specimen transport vial (packed in collection cup) / 30mL minimum transported in specimen transport vial without any additives or preservatives

Transport - Room temperature

Specimen Stability - Room temperature for 7 days, refrigerated 14 days, frozen 14 days

Specimen Rejection - Preserved samples, sample cup without ID, leaked in transport

IMPORTANT MEDICARE INFORMATION TO THE BENEFICIARY: ADVANCED BENIFICIARY NOTICE (ABN)

Your physician may sometimes order laboratory testing that he or she believes to be necessary for your care, but which does not quality for coverage under your Insurance Provider's and Medicare's standards. Insurance Providers and Medicare will only pay for services that it determines to be "reasonable and necessary" based upon the diagnosis information furnished to Clarity Laboratory by your physician. If, under your Insurance Provider's and Medicare's standards, your diagnosis does not support the testing ordered, your Insurance Providers and Medicare will deny coverage. In those cases where your Insurance Providers and Medicare denies coverage, the billing will be forwarded to you, and you will be responsible for the cost of the laboratory tests.

TO THE PROVIDER: Covered Indication for UDT (LCD L36037)

MEDICAL NECESSITY GUIDANCE:

DIAGNOSIS AND TREATMENT FOR SUBSTANCE ABUSE OR DEPENDENCE

UDT is a medically necessary and useful component of chemical dependency diagnosis and treatment. The UDT result influences treatment and level of care decisions. Ordered tests and testing methods (presumptive and/or definitive) must match) the stage of screening, treatment, or recovery; the documented history; and Diagnostic and Statistical Manual of Mental Disorders (DSM diagnosis. For patients with no known indicators of risk for SUDs, the clinician may screen for a broad range of commonly abused drugs using presumptive UDT. For patients with known indicators of risk for SUDs, the clinician may screen for a broad range of commonly abused drugs using definitive UDT. For patients with a diagnosed SUD, the clinician should perform random UDT, at random intervals in order to properly monitor the patient. Testing profiles must be determined by the clinician based on the following medical necessity guidance criteria: Patient history, physical examination, and previous laboratory findings; Stage of treatment or recovery; Suspected abused substance; Substances that may present high risk for additive or synergistic interactions with prescribed medication (e.g.,benzodiazepines, alcohol). The patient's medical record must include an appropriate testing frequency based on the stage of screening, treatment, or recovery; the rationale for the drugs/drug classes ordered; and the results must be documented in the medical record and used to direct care.

FREQUENCY OF UDT FOR SUD:

The testing frequency must meet medical necessity and be documented in the clinician's medical record.

TREATMENT FOR PATIENTS ON CHRONIC OPIOID THERAPY (COT).

Criteria to establish medical necessity for drug testing must be based on patient-specific elements identified during the clinical assessment, and documented by the clinician in the patient's medical record and minimally include the following elements: Patient history, physical examination and previous laboratory findings; Current treatment plan; Prescribed medication(s); Risk assessment plan.

COT BASELINE TESTING:

Initial presumptive and/or definitive COT patient testing may include amphetamine/ methamphetamine, barbiturates, benzodiazepines, cocaine, methadone, oxycodone, tricyclic antidepressants, THC, opioids, opiates, heroin, and synthetic/analog or "designer" drugs.

COT MONITORING TESTING:

Ongoing testing may be medically reasonable and necessary based on the patient history, clinical assessment, including medication side effects or inefficacy, suspicious behaviors, self-escalation of dose, doctor-shopping, indications/symptoms of illegal drug use, evidence of diversion, or other clinician documented change in affect or behavioral pattern. The frequency of testing must be based on a complete clinical assessment of the individual's risk potential for abuse and diversion using a validated risk assessment interview or questionnaire and should include the patient's response to prescribed medications and the side effects of medications. The clinician should perform random UDT at random intervals, in order to properly monitor a patient. UDT testing does not have to be associated with an office visit. Patients with specific symptoms of medication aberrant behavior or misuse may be tested in accordance with this document's guidance for monitoring patient adherence and compliance during active treatment (<90 days) for substance use or dependence.

NON-COVERED SERVICES

- 1. Blanket Orders
- 2. Reflex definitive UDT is not reasonable and necessary when presumptive testing is performed at point of care because the clinician may have sufficient information to manage the patient. If the clinician is not satisfied, he/she must determine the clinical appropriateness of and order specific subsequent definitive testing (e.g., the patient admits to using a particular drug, or the IA cut-off is set at such a point that is sufficiently low that the physician is satisfied with the presumptive test result).
- 3. Routine standing orders for all patients in a physician's practice are not reasonable and necessary.
- 4. It is not reasonable and necessary for a physician to perform presumptive POCT (or IA testing) and order presumptive IA testing from a reference laboratory. Medicare will only pay for one presumptive test result per patient per date of service regardless of the number of billing providers.
- 5. It is not reasonable and necessary for a reference laboratory to perform and bill IA presumptive UDT prior to definitive testing without a specific physician's order for the presumptive testing.
- 6. Drug testing of two different specimen types from the same patient on the same date of service for the same drugs/metabolites/analytes.
 - 7. UDT for medico-legal and/or employment purposes or to protect a physician from drug diversion charges.
 - 8. Specimen validity testing including, but not limited to, pH, specific gravity, oxidants, creatinine.

The Office of Inspector General (OIG) takes the position that a physician who orders medically unnecessary test for which Medicare reimbursement is claimed may be subject to civil penalties. Physicians should only order tests they deem medically necessary,